Experimental 'Double-Target' cell therapy takes on tough lymphomas
NCT ID NCT07168291
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 40 times
Summary
This early-phase trial tests a new type of immune cell therapy called bispecific AbTCR T-cells in just 3 adults with relapsed or refractory B-cell lymphoma. The cells are designed to attack two targets (CD19 and CD22) on cancer cells. The main goal is to check safety, and secondarily to see if the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bispecific AbTCR (anti-CD19/CD22)-T cells
What this could lead to
If it works, this could point toward a new treatment option for patients with hard-to-treat B-cell lymphomas.
What could go wrong
This is a very early, tiny trial (only 3 people) focused on safety, not effectiveness. The treatment may cause serious side effects and may not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.